Please login to the form below

Not currently logged in
Email:
Password:

turoctocog alfa

This page shows the latest turoctocog alfa news and features for those working in and with pharma, biotech and healthcare.

EMA clears Novo Nordisk’s long-acting haemophilia A drug

EMA clears Novo Nordisk’s long-acting haemophilia A drug

Esperoct (turoctocog alfa pegol) is a follow-up to Novo Nordisk’s NovoEight product and allows patients to inject themselves once every four days, rather than every other day or three

Latest news

  • CHMP nod for Alexion, GSK drugs, revocation for Lartruvo CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

    Novo Nordisk’s haemophilia A treatment Esperoct (turoctocog alfa pegol), a longer-acting extended half-life factor VIII molecule, which allows patients to inject themselves once every four days, rather than

  • US approval for Novo's Factor XIII drug Tretten US approval for Novo's Factor XIII drug Tretten

    In October, Novo secured US approval for NovoEight, a new long-acting Factor VIII for people with haemophilia A (turoctocog alfa), while it also has NN7999, a long-acting recombinant coagulation ... The company suffered a disappointment last year when it

  • EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK EMA backs drugs from Novo, Otsuka, AZ, Janssen, GSK

    Novo Nordisk's haemophilia drug. Among the drugs backed by the CHMP, which provides guidance to the European Medicines Agency (EMA), was Novo Nordisk's NovoEight (turoctocog alfa) for use in

More from news
Approximately 0 fully matching, plus 4 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics